Our top pick for
Kamada Ltd is a drug manufacturers-specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Kamada employs 408 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.27|
|52-week range||$5.11 - $8.85|
|50-day moving average||$5.32|
|200-day moving average||$5.69|
|Wall St. target price||$11.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-0.19%|
|1 month (2021-09-17)||-1.86%|
|3 months (2021-07-16)||-5.05%|
|6 months (2021-04-16)||-14.59%|
|1 year (2020-10-16)||-33.71%|
|2 years (2019-10-17)||-0.38%|
|3 years (2018-10-17)||5.97|
|5 years (2016-10-17)||5.67|
Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Kamada shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.4 million.
The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$116 million|
|Operating margin TTM||12.51%|
|Gross profit TTM||$47.6 million|
|Return on assets TTM||4.29%|
|Return on equity TTM||6.87%|
|Market capitalisation||$236.3 million|
TTM: trailing 12 months
There are currently 721,835 Kamada shares held short by investors – that's known as Kamada's "short interest". This figure is 1.8% down from 734,822 last month.
There are a few different ways that this level of interest in shorting Kamada shares can be evaluated.
Kamada's "short interest ratio" (SIR) is the quantity of Kamada shares currently shorted divided by the average quantity of Kamada shares traded daily (recently around 29741.862381541). Kamada's SIR currently stands at 24.27. In other words for every 100,000 Kamada shares traded daily on the market, roughly 24270 shares are currently held short.
However Kamada's short interest can also be evaluated against the total number of Kamada shares, or, against the total number of tradable Kamada shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kamada's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kamada shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Kamada shares, roughly 24 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Kamada.
Find out more about how you can short Kamada stock.
We're not expecting Kamada to pay a dividend over the next 12 months.
Over the last 12 months, Kamada's shares have ranged in value from as little as $5.11 up to $8.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.3067. This would suggest that Kamada's shares are less volatile than average (for this exchange).
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.